FDA granted regular approval to Venclexta venetoclax alone or in combination with Rituxan rituximab to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in patients with or without the 17p deletion who have...

FDA granted regular approval to Venclexta venetoclax alone or in combination with Rituxan rituximab to treat chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in patients with or without the 17p deletion who have...

Unity Biotechnology Inc. (NASDAQ:UBX) raised $85 million late May 2 through the sale of 5 million shares at $17 in an IPO underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho. The price was at...

Unity Biotechnology Inc. (NASDAQ:UBX) raised $85 million late Wednesday through the sale of 5 million shares at $17 in an IPO underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho. The price was at the...

On April 5, Unity Biotechnology Inc. (Brisbane, Calif.) filed to raise up to $85 million in an IPO on NASDAQ underwritten by Goldman Sachs, Morgan Stanley, Citigroup and Mizuho.
Unity's lead candidates target senescent cells to...